In the BioHarmony Drug Report Database
Somatuline Depot (lanreotide) is a protein pharmaceutical. Lanreotide was first approved as Somatuline Depot on 2007-08-30. It is used to treat acromegaly and neuroendocrine tumors in the USA. The pharmaceutical is active against somatostatin receptor type 2 and somatostatin receptor type 5. In addition, it is known to target somatostatin receptor type 3.
Image (chem structure or protein)